WO2009056862A3 - Dépistage de la susceptibilité au cancer de la prostate - Google Patents

Dépistage de la susceptibilité au cancer de la prostate Download PDF

Info

Publication number
WO2009056862A3
WO2009056862A3 PCT/GB2008/003711 GB2008003711W WO2009056862A3 WO 2009056862 A3 WO2009056862 A3 WO 2009056862A3 GB 2008003711 W GB2008003711 W GB 2008003711W WO 2009056862 A3 WO2009056862 A3 WO 2009056862A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
genes
snp
individuals
psp94
Prior art date
Application number
PCT/GB2008/003711
Other languages
English (en)
Other versions
WO2009056862A2 (fr
Inventor
Rosalind Eeles
Douglas Easton
David Austin Neal
Graham Giles
Original Assignee
Cancer Rec Tech Ltd
Rosalind Eeles
Douglas Easton
David Austin Neal
Graham Giles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd, Rosalind Eeles, Douglas Easton, David Austin Neal, Graham Giles filed Critical Cancer Rec Tech Ltd
Publication of WO2009056862A2 publication Critical patent/WO2009056862A2/fr
Publication of WO2009056862A3 publication Critical patent/WO2009056862A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un panneau de marqueurs de la susceptibilité au cancer de la prostate permet le dépistage pour identifier des personnes à haut risque de développer le cancer de la prostate. On peut offrir à de telles personnes un suivi et une gestion cliniques plus rapprochés pour assurer un diagnostic et une intervention au moment opportun. On a observé qu'un nombre de polymorphismes simple nucléotide (SNP) se lient à des sites/gènes qui sont susceptibles de jouer des rôles fonctionnel/causal dans le cancer de la prostate. Le SNP les plus étroitement associés (rs 10993994) est le 2bp en amont du site de début de la transcription du gène MSMB. Le gène MSMB code pour le PSP94 qui est un facteur de liaison à l'immunoglobuline qui est produit par les cellules épithéliales de la prostate et sécrété dans le fluide séminal. Il a été établi que la perte de PSP94 est associée à la récurrence tumorale chez des patients suivant une prostatectomie. La seconde association en termes d'importance est pour le SNP rs2735839 qui se situe entre les gènes de la kallikréine-2 et -3. Ces gènes ont également été liés au cancer de la prostate et proposés comme marqueurs possibles. D'autres SNP sont associés de manière significative à la susceptibilité de personnes au cancer de la prostate.
PCT/GB2008/003711 2007-11-02 2008-10-31 Dépistage de la susceptibilité au cancer de la prostate WO2009056862A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0721605.4 2007-11-02
GB0721605A GB0721605D0 (en) 2007-11-02 2007-11-02 Prostrate cancer susceptibility screening

Publications (2)

Publication Number Publication Date
WO2009056862A2 WO2009056862A2 (fr) 2009-05-07
WO2009056862A3 true WO2009056862A3 (fr) 2009-07-23

Family

ID=38834783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003711 WO2009056862A2 (fr) 2007-11-02 2008-10-31 Dépistage de la susceptibilité au cancer de la prostate

Country Status (2)

Country Link
GB (1) GB0721605D0 (fr)
WO (1) WO2009056862A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101752499B1 (ko) 2008-06-04 2017-06-29 모디퀘스트 비.브이. 소염제
EP3556870B9 (fr) 2010-07-27 2022-09-28 Genomic Health, Inc. Procédé d'utilisation de l'expression génique pour déterminer le pronostic du cancer de la prostate
WO2012029080A1 (fr) * 2010-08-30 2012-03-08 Decode Genetics Ehf Variants de séquence associés à des taux d'antigène spécifique de la prostate
EP2611943B1 (fr) * 2010-09-03 2017-01-04 Wake Forest University Health Sciences Procédés et compositions pour la corrélation de marqueurs génétiques au risque de cancer de la prostate
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
CN103060432B (zh) * 2012-10-19 2014-07-23 卫生部北京医院 一种预测前列腺癌易感性的方法和检测试剂盒
CN103060434B (zh) * 2012-10-19 2014-07-23 卫生部北京医院 一种预测前列腺癌易感性的试剂和方法
CN103432593B (zh) * 2013-08-01 2015-04-15 中山大学附属肿瘤医院 一种用于预防或治疗食管癌的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009814A2 (fr) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
WO2005007830A2 (fr) * 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Procedes et compositions pour diagnostic, stadage et pronostic du cancer de la prostate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009814A2 (fr) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
WO2005007830A2 (fr) * 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Procedes et compositions pour diagnostic, stadage et pronostic du cancer de la prostate

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AMUNDADOTTIR L T ET AL: "A common variant associated with prostate cancer in European and African populations", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 38, no. 6, 7 May 2006 (2006-05-07), pages 652 - 658, XP002396336, ISSN: 1061-4036 *
BEKE L ET AL: "The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2", ONCOGENE, vol. 26, no. 31, July 2007 (2007-07-01), pages 4590 - 4595, XP002513955, ISSN: 0950-9232 *
BUCKLAND PAUL R ET AL: "Strong bias the location of functional promoter polymorphisms", HUMAN MUTATION, vol. 26, no. 3, September 2005 (2005-09-01), pages 214 - 223, XP002513954, ISSN: 1059-7794 *
EELES ROSALIND A ET AL: "Multiple newly identified loci associated with prostate cancer susceptibility", NATURE GENETICS, vol. 40, no. 3, March 2008 (2008-03-01), pages 316 - 321, XP002513956, ISSN: 1061-4036 *
NAM ET AL: "A Novel Serum Marker, Total Prostate Secretory Protein of 94 Amino Acids, Improves Prostate Cancer Detection and Helps Identify High Grade Cancers at Diagnosis", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 175, no. 4, 1 April 2006 (2006-04-01), pages 1291 - 1297, XP005363045, ISSN: 0022-5347 *
SCHAID D J: "The complex genetic epidemiology of prostate cancer", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, vol. 13, no. REVIEW NR 1, 28 January 2004 (2004-01-28), pages R103 - R121, XP002396337, ISSN: 0964-6906 *
THOMAS GILLES ET AL: "Multiple loci identified in a genome-wide association study of prostate cancer", NATURE GENETICS, vol. 40, no. 3, March 2008 (2008-03-01), pages 310 - 315, XP002513957, ISSN: 1061-4036 *

Also Published As

Publication number Publication date
GB0721605D0 (en) 2007-12-12
WO2009056862A2 (fr) 2009-05-07

Similar Documents

Publication Publication Date Title
WO2009056862A3 (fr) Dépistage de la susceptibilité au cancer de la prostate
Rajaraman et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults
Bryan et al. Mechanisms of recurrence of Ta/T1 bladder cancer
Goh et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications
WO2008146309A3 (fr) Variantes génétiques sur les chr 5p12 et 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2006110264A3 (fr) Procedes et compositions permettant de predire le deces du au cancer et la survie au cancer de la prostate a l'aide de signatures d'expression genique
Zeng et al. Polymorphisms in prostate stem cell antigen gene rs2294008 increase gastric cancer risk in Chinese
WO2007084992A3 (fr) Marqueurs prédictifs utilisés à des fins de pronostic et de traitement et leurs méthodes d'utilisation
WO2012018613A3 (fr) Modification de l'issue des cancers suivant la constitution génétique
Yuan et al. LncRNA PCAT1 and its genetic variant rs1902432 are associated with prostate cancer risk
CR9100A (es) Metodos y sistemas para el pronostico y tratamiento de tumores solidos
EP2540840A3 (fr) Variants génétiques du CHR16 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
NZ596070A (en) Genetic variants contributing to risk of prostate cancer
Lin et al. Polymorphisms of long non-coding RNA HOTAIR with breast cancer susceptibility and clinical outcomes for a southeast Chinese Han population
WO2008088860A3 (fr) Polymorphismes présents dans la voie de signalisation de l'egfr utilisés comme marqueurs pour le traitement du cancer
Chang et al. Ferroptosis-related gene signature accurately predicts survival outcomes in patients with clear-cell renal cell carcinoma
Gaudet et al. No association between FTO or HHEX and endometrial cancer risk
WO2012031207A3 (fr) Procédés et compositions pour la corrélation de marqueurs génétiques au risque de cancer de la prostate
WO2006099259A3 (fr) Nouvelles mutations faux-sens et polymorphismes a simple nucleotide dans le gene du type rabphillin-3a et utilisations correspondantes
Yang et al. p21 Waf1/Cip1 polymorphisms and risk of esophageal cancer
Broberg et al. Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study
Eo et al. A pathway-based classification of breast cancer integrating data on differentially expressed genes, copy number variations and MicroRNA target genes
Parikh et al. A comprehensive resequence analysis of the KLK15–KLK3–KLK2 locus on chromosome 19q13. 33
Nan et al. Missense polymorphisms in matrix metalloproteinase genes and skin cancer risk
Murali et al. Loss of heterozygosity of D9S162: molecular predictor for treatment response in oral carcinoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08845891

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08845891

Country of ref document: EP

Kind code of ref document: A2